Literature DB >> 24312874

Dampening of Serotonergic System through 5HT1A Receptors is a Promising Target for Treatment of Levodopa Induced Motor Problems.

Javad Mahmoudi1, Mehdi Farhoudi, Siamak Reyhani-Rad, Saeed Sadigh-Eteghad.   

Abstract

During long-term treatment with Levodopa, majority of patients with Parkinson's disease experience some abnormal motor problems including of Levodopa induced dyskinesia (LID) and wearing off. Incredible evidences suggest that serotonergic neurons compensate some functions of lost dopaminergic neurons in Parkinson's disease especially in advanced disease stages. Therefore, it has been postulated that serotonergic neurons are the major source for development of these unwanted effects. 5HT1A receptors are located on the serotonergic neurons and are involved in regulation of normal motor functions. With respect to the role of serotonergic projection in Parkinson's disease and importance of 5HT1A receptors in motor activity it seems that inactivation of these neurons by stimulation of 5HT1A receptors could provide benefits in treatment of Levodopa induced motor impairments.

Entities:  

Keywords:  5HT1A receptor; Compensatory co-transmission; Dopaminergic neurons; Levodopa; Serotonergic neurons

Year:  2013        PMID: 24312874      PMCID: PMC3848224          DOI: 10.5681/apb.2013.071

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  19 in total

Review 1.  Continuous dopamine-receptor stimulation in advanced Parkinson's disease.

Authors:  J G Nutt; J A Obeso; F Stocchi
Journal:  Trends Neurosci       Date:  2000-10       Impact factor: 13.837

Review 2.  Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Martin Lundblad
Journal:  J Neurochem       Date:  2006-08-29       Impact factor: 5.372

3.  Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.

Authors:  Manolo Carta; Thomas Carlsson; Ana Muñoz; Deniz Kirik; Anders Björklund
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

4.  Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions.

Authors:  Kazuo Matsubara; Keiko Shimizu; Manabu Suno; Kento Ogawa; Toshio Awaya; Takehiro Yamada; Toshihiro Noda; Machiko Satomi; Ko-ichi Ohtaki; Kaoru Chiba; Yoshikazu Tasaki; Hiroshi Shiono
Journal:  Brain Res       Date:  2006-08-01       Impact factor: 3.252

5.  Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

Authors:  Manolo Carta; Thomas Carlsson; Deniz Kirik; Anders Björklund
Journal:  Brain       Date:  2007-04-23       Impact factor: 13.501

Review 6.  Levodopa in the early treatment of Parkinson's disease.

Authors:  Miho Murata
Journal:  Parkinsonism Relat Disord       Date:  2009-01       Impact factor: 4.891

7.  Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.

Authors:  Elyse S Kemmerer; Timothy J Desmond; Roger L Albin; Michael R Kilbourn; Kirk A Frey
Journal:  Exp Neurol       Date:  2003-09       Impact factor: 5.330

8.  Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT(1A) recaptors.

Authors:  A Mohajjel Nayebi A; H Sheidaei
Journal:  Daru       Date:  2010       Impact factor: 3.117

9.  5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats.

Authors:  J Mahmoudi; A Mohajjel Nayebi; M Samini; S Reyhani-Rad; V Babapour
Journal:  Daru       Date:  2011       Impact factor: 3.117

Review 10.  Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

Authors:  Emma Lane; Stephen Dunnett
Journal:  Psychopharmacology (Berl)       Date:  2007-09-25       Impact factor: 4.530

View more
  2 in total

Review 1.  Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review.

Authors:  Fereshteh Farajdokht; Saeed Sadigh-Eteghad; Alireza Majdi; Fariba Pashazadeh; Seyyed Mehdi Vatandoust; Mojtaba Ziaee; Fatemeh Safari; Pouran Karimi; Javad Mahmoudi
Journal:  EXCLI J       Date:  2020-03-02       Impact factor: 4.068

2.  Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson's Disease; Possible Involvement of Dopaminergic Neurotransmission.

Authors:  Reza Vajdi-Hokmabad; Mojtaba Ziaee; Saeed Sadigh-Eteghad; Siamak Sandoghchian Shotorbani; Javad Mahmoudi
Journal:  Adv Pharm Bull       Date:  2017-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.